• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pericardial events associated with ibrutinib-based therapies for chronic lymphocytic leukaemia in two landmark trials.两项具有里程碑意义的试验中与基于伊布替尼的慢性淋巴细胞白血病治疗相关的心包事件。
Br J Haematol. 2024 Oct;205(4):1645-1648. doi: 10.1111/bjh.19710. Epub 2024 Sep 1.
2
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.乌布利昔单抗、乌姆布利西布和伊布替尼在慢性淋巴细胞白血病和非霍奇金淋巴瘤患者中的耐受性和活性：一项1期剂量递增和扩展试验
Lancet Haematol. 2019 Feb;6(2):e100-e109. doi: 10.1016/S2352-3026(18)30216-3.
3
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.依鲁替尼联合氟达拉滨、环磷酰胺和利妥昔单抗作为年轻慢性淋巴细胞白血病患者的初始治疗：一项单臂、多中心、2期试验。
Lancet Haematol. 2019 Aug;6(8):e419-e428. doi: 10.1016/S2352-3026(19)30104-8. Epub 2019 Jun 14.
4
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.依鲁替尼联合纳武单抗治疗复发非霍奇金淋巴瘤或慢性淋巴细胞白血病患者的安全性和活性：一项1/2a期研究
Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.
5
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.Umbralisib联合伊布替尼治疗复发或难治性慢性淋巴细胞白血病或套细胞淋巴瘤患者：一项多中心1-1b期研究
Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14.
6
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.伊布替尼治疗伴有 17p 缺失的复发或难治性慢性淋巴细胞白血病患者（RESONATE-17）：一项 2 期、开放标签、多中心研究。
Lancet Oncol. 2016 Oct;17(10):1409-1418. doi: 10.1016/S1470-2045(16)30212-1. Epub 2016 Sep 13.
7
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.奥妥珠单抗联合伊布替尼诱导治疗，随后采用微小残留病驱动策略治疗慢性淋巴细胞白血病患者（ICLL07 FILO）：一项单臂、多中心、2期试验。
Lancet Haematol. 2019 Sep;6(9):e470-e479. doi: 10.1016/S2352-3026(19)30113-9. Epub 2019 Jul 16.
8
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.乌布利昔单抗联合伊布替尼与伊布替尼单药治疗复发或难治性高危慢性淋巴细胞白血病患者（GENUINE）：一项 3 期、多中心、开放标签、随机试验。
Lancet Haematol. 2021 Apr;8(4):e254-e266. doi: 10.1016/S2352-3026(20)30433-6. Epub 2021 Feb 22.
9
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.伊布替尼联合苯达莫司汀和利妥昔单抗对比安慰剂、苯达莫司汀和利妥昔单抗治疗既往治疗的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤（HELIOS）：一项随机、双盲、III 期研究。
Lancet Oncol. 2016 Feb;17(2):200-211. doi: 10.1016/S1470-2045(15)00465-9. Epub 2015 Dec 5.
10
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.伊布替尼联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病（ILLUMINATE）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3.

引用本文的文献

1
Risk of drug-induced pericardial effusion: a disproportionality analysis of the FAERS database.药物性心包积液的风险：对FDA不良事件报告系统（FAERS）数据库的不成比例性分析
BMC Pharmacol Toxicol. 2025 Feb 7;26(1):27. doi: 10.1186/s40360-025-00867-6.

本文引用的文献

1
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.伊布替尼-利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的长期疗效：E1912 试验的更新结果。
Blood. 2022 Jul 14;140(2):112-120. doi: 10.1182/blood.2021014960.
2
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.RESONATE-2 研究的 8 年随访结果：伊布替尼一线治疗慢性淋巴细胞白血病患者。
Blood Adv. 2022 Jun 14;6(11):3440-3450. doi: 10.1182/bloodadvances.2021006434.
3
Arrhythmia Patterns in Patients on Ibrutinib.接受依鲁替尼治疗患者的心律失常模式
Front Cardiovasc Med. 2022 Jan 3;8:792310. doi: 10.3389/fcvm.2021.792310. eCollection 2021.
4
Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy.伊布替尼治疗患者心房颤动发展的决定因素。
Clin Med Res. 2022 Mar;20(1):16-22. doi: 10.3121/cmr.2021.1693. Epub 2022 Jan 12.
5
Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database.伊布替尼的安全性概况：对世界卫生组织药物警戒数据库的分析
Front Pharmacol. 2021 Oct 28;12:769315. doi: 10.3389/fphar.2021.769315. eCollection 2021.
6
Cardiovascular Toxicities Associated With Ibrutinib.伊布替尼相关心血管毒性。
J Am Coll Cardiol. 2019 Oct 1;74(13):1667-1678. doi: 10.1016/j.jacc.2019.07.056.
7
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.RESONATE 最终分析：先前接受治疗的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者接受伊布替尼治疗的最长六年随访结果。
Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13.
8
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.伊布替尼联合利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的比较
N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.
9
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.伊布替尼治疗与细胞毒性化疗相比患者的心房心律失常发生率和风险。
Am J Cardiol. 2019 Aug 15;124(4):539-544. doi: 10.1016/j.amjcard.2019.05.029. Epub 2019 May 25.
10
Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium.伊布替尼通过诱导心房结构重塑和钙稳态失调促进心房颤动。
Heart Rhythm. 2019 Sep;16(9):1374-1382. doi: 10.1016/j.hrthm.2019.04.008. Epub 2019 Apr 5.

两项具有里程碑意义的试验中与基于伊布替尼的慢性淋巴细胞白血病治疗相关的心包事件。

Pericardial events associated with ibrutinib-based therapies for chronic lymphocytic leukaemia in two landmark trials.

作者信息

Fakhri Bita, Wang Victoria, Perez-Burbano Gabriela, Wall Anna, Mandrekar Sumithra, Parikh Sameer A, Woyach Jennifer, Shanafelt Tait

机构信息

Stanford University School of Medicine, Palo Alto, California, USA.

Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

出版信息

Br J Haematol. 2024 Oct;205(4):1645-1648. doi: 10.1111/bjh.19710. Epub 2024 Sep 1.

DOI:10.1111/bjh.19710
PMID:39219152
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11486548/
Abstract

In the past decade, ibrutinib has transformed the treatment landscape for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Two pivotal US Intergroups trials (E1912 and A041202) have established ibrutinib as the frontline treatment option for patients with treatment-naïve CLL in both young and fit, and old and frail populations. The cardiovascular side effect profile such as cardiac dysrhythmias, ischemic events and hypertension continues to be meticulously reported in all trials investigating ibrutinib and all other Bruton tyrosine kinase inhibitors for CLL/SLL. Herein, we utilized pooled data from two pivotal US Intergroup trials (A041202 and E1912) to report and evaluate ibrutinib associated pericardial events (including pericardial effusion, pericarditis, and tamponade).

摘要

在过去十年中，伊布替尼改变了慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）的治疗格局。两项关键的美国协作组试验（E1912和A041202）已将伊布替尼确立为初治CLL患者在年轻健康人群以及老年体弱人群中的一线治疗选择。在所有针对CLL/SLL研究伊布替尼及所有其他布鲁顿酪氨酸激酶抑制剂的试验中，诸如心律失常、缺血性事件和高血压等心血管副作用情况仍在被详细报告。在此，我们利用两项美国协作组关键试验（A041202和E1912）的汇总数据来报告和评估与伊布替尼相关的心包事件（包括心包积液、心包炎和心脏压塞）。